See more : Softfront Holdings (2321.T) Income Statement Analysis – Financial Results
Complete financial analysis of INmune Bio, Inc. (INMB) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of INmune Bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Tan Chong International Limited (0693.HK) Income Statement Analysis – Financial Results
- MamaMancini’s Holdings, Inc. (MMMB) Income Statement Analysis – Financial Results
- Jutal Offshore Oil Services Limited (3303.HK) Income Statement Analysis – Financial Results
- MetaTech (AP) Inc. (3224.TWO) Income Statement Analysis – Financial Results
- Fast Ejendom Danmark A/S (FED.CO) Income Statement Analysis – Financial Results
INmune Bio, Inc. (INMB)
About INmune Bio, Inc.
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 155.00K | 374.00K | 181.00K | 10.92K | 77.69M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 155.00K | 374.00K | 181.00K | 10.92K | 77.69M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 20.27M | 17.07M | 20.54M | 5.92M | 3.28M | 1.11M | 435.36K | 101.50K | 0.00 |
| General & Administrative | 9.62M | 9.26M | 8.79M | 6.32M | 6.02M | 11.33M | 546.12K | 126.00K | 195.47K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -146.60K |
| SG&A | 9.62M | 9.26M | 8.79M | 6.32M | 6.02M | 11.33M | 546.12K | 126.00K | 48.87K |
| Other Expenses | 0.00 | -1.35M | -1.19M | 128.52K | 0.00 | 0.00 | -6.00 | 0.00 | 0.00 |
| Operating Expenses | 29.90M | 26.33M | 29.33M | 12.24M | 9.30M | 12.44M | 981.48K | 227.49K | 48.87K |
| Cost & Expenses | 29.90M | 26.33M | 29.33M | 12.24M | 9.30M | 12.44M | 981.48K | 227.49K | 48.87K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 77.69K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 1.35M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 0.00 | 25.95M | 29.15M | 12.23M | 9.30M | 12.44M | 981.48K | 227.49K | 195.47K |
| EBITDA | -29.74M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 149.99K | -50.00K | 146.60K |
| EBITDA Ratio | -19,187.74% | -6,938.77% | -16,106.63% | -112,016.09% | -13.95% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -29.74M | -25.95M | -29.15M | -12.23M | -7.76M | -12.44M | -981.48K | -227.49K | -48.87K |
| Operating Income Ratio | -19,187.74% | -6,938.77% | -16,106.63% | -112,016.09% | -9.98% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -267.00K | -1.35M | -1.19M | 129.00K | 77.69K | 0.00 | 149.99K | -50.00K | 0.00 |
| Income Before Tax | -30.01M | -27.30M | -30.34M | -12.10M | -7.68M | -12.44M | -831.49K | -277.49K | -48.87K |
| Income Before Tax Ratio | -19,360.00% | -7,299.20% | -16,762.43% | -110,838.76% | -9.88% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 1.35M | -29.15M | -12.23M | 1.46M | -161.14K | -1.13M | -177.49K | 0.00 |
| Net Income | -30.01M | -28.65M | -30.34M | -12.10M | -9.14M | -12.44M | -831.49K | -277.49K | -48.87K |
| Net Income Ratio | -19,360.00% | -7,659.63% | -16,762.43% | -110,838.76% | -11.77% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.67 | -1.60 | -1.88 | -1.01 | -0.89 | -1.11 | -0.07 | -0.02 | 0.00 |
| EPS Diluted | -1.67 | -1.60 | -1.88 | -1.01 | -0.89 | -1.11 | -0.07 | -0.02 | 0.00 |
| Weighted Avg Shares Out | 17.98M | 17.93M | 16.13M | 11.99M | 10.27M | 11.22M | 11.22M | 11.22M | 11.22M |
| Weighted Avg Shares Out (Dil) | 17.98M | 17.93M | 16.13M | 11.99M | 10.27M | 11.22M | 11.22M | 11.22M | 11.22M |
INmune Bio, Inc. to Report Third Quarter 2021 Financial Results and Provide a Corporate Update on Wednesday, November 3
Management to host conference call and webcast at 4:30 pm ET on that day Management to host conference call and webcast at 4:30 pm ET on that day
INmune Bio A No-Brainer Investment
GameStop stock continues to defy the Street logic. Its fans are willing to stick around with Ryan Cohen & Co. for the long term. Matt Furlong & the team did not announce anything substantial on its restructuring plans in the...
INmune Bio, Inc. to Participate in the B. Riley Fall 2021 Best Ideas in Oncology Series
Boca Raton, FL, Sept. 27, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the, “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announced that Mark Lowdell, PhD,...
INmune Bio, Inc. Announces Participation at Upcoming Investor Conferences
BOCA RATON, Florida, Sept. 20, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announced that Raymond J. Tesi,...
INMB Stock: Explanation For Over 30% Increase This Week
The stock price of INmune Bio Inc (NASDAQ: INMB) increased by over 30% this week. This is why it happened.
Why Are Shares Of INmune Bio Trading Higher Wednesday Afternoon?
INmune Bio, Inc. (NASDAQ: INMB) shares traded higher Wednesday afternoon following data out of a trial for the company's Alzheimer's drug candidate. The company said its selective dominant-negative tumor necrosis factor inhibitor candidate for the treatment of Alzheimer's disease, XPro...
Alzheimer's Patients Treated with INmune Bio's XPro™ Show Reduction in CSF Phospho-Tau and Evidence of Remyelination
XPro™ treatment shows statistically significant decrease in Phospho Tau 217 (pT271) and pT181, and an improvement in an imaging biomarker of myelination. XPro™ treatment shows statistically significant decrease in Phospho Tau 217 (pT271) and pT181, and an improvement in an...
INmune Bio, Inc. Announces Biomarker Data Demonstrating that the First Patient Treated with its NK Cell Priming “Pseudokine”, INKmune™, Successfully Produced Memory-Like NK Cells
First positive clinical confirmation of in vivo NK response, mirroring in vitro data
Our Bullish Take On INmune Bio's Drug Pipeline
Our Bullish Take On INmune Bio's Drug Pipeline
INmune Bio, Inc. to Present at the Canaccord Genuity 41st Annual Growth Conference
BOCA RATON, Florida, Aug. 10, 2021 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient's innate immune system to fight disease, today announced that Raymond J. Tesi, MD,...
Source: https://incomestatements.info
Category: Stock Reports